The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Rescuing the function of mutant p53
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
MOLMOL: A program for display and analysis of macromolecular structures
Koradi, R., Billeter, M., & Wüthrich, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00009-4 · Cited by 7,163
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
T antigen is bound to a host protein in SY40-transformed cells
LANE, D. P., & CRAWFORD, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,394
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“So, too little p53 allows cancer cells to proliferate, as exploited by oncogenic viruses, whereas too much p53 can be lethal, as witnessed in Mdm2 knockout mic”
BackgroundThe Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,409
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Mechanism-Based Target Identification and Drug Discovery in Cancer Research
Gibbs, J. B. (2000) · Science · doi:10.1126/science.287.5460.1969 · Cited by 606
Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms
Jeffrey, P. D., Gorina, S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 549
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Pavletich, N. P., Chambers, K. A., & Pabo, C. O. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2556 · Cited by 521
The function of PML in p53-dependent apoptosis
Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., & Paolo Pandolfi, P. (2000) · Nature Cell Biology · doi:10.1038/35036365 · Cited by 472
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Small peptides activate the latent sequence-specific DNA binding function of p53
Hupp, T. R., Sparks, A., & Lane, D. P. (1995) · Cell · doi:10.1016/0092-8674(95)90165-5 · Cited by 434
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 434
Self-citationThermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
Self-citationp53 is associated with cellular microtubules and is transported to the nucleus by dynein
Giannakakou, P., Sackett, D. L., Ward, Y., Webster, K. R., Blagosklonny, M. V., & Fojo, T. (2000) · Nature Cell Biology · doi:10.1038/35036335 · Cited by 373
Regulation of p53 activity in nuclear bodies by a specific PML isoform
Fogal, V. (2000) · The EMBO Journal · doi:10.1093/emboj/19.22.6185 · Cited by 372
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 342
Structure of the negative regulatory domain of p53 bound to S100B(betabeta).
Weber, D. J., Rust, R. R., & Baldisseri, D. M. (2000) · Nature Structural Biology · doi:10.1038/76797 · Cited by 314
Allosteric activation of latent p53 tetramers
Hupp, T. R., & Lane, D. P. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00195-0 · Cited by 301
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
Solution structure of the tetrameric minimum transforming domain of p53
Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability
Nikolova, P. V., Henckel, J., Lane, D. P., & Fersht, A. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14675 · Cited by 240
Self-citationPhysical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 240
Activation of p53 in cervical carcinoma cells by small molecules
Hietanen, S., Lain, S., Krausz, E., Blattner, C., & Lane, D. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8501 · Cited by 230
Refined solution structure of the oligomerization domain of the tumour suppressor p53
Clore, G. M., Ernst, J., Clubb, R., Omichinski, J. G., Kennedy, W. M. P., Sakaguchi, K., Appella, E., & Gronenborn, A. M. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-321 · Cited by 222
Hot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K.-B., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 221
Self-citationP53 tumor suppressor gene therapy for cancer.
Nielsen, L. L., & Maneval, D. C. (1998) · PubMed · Cited by 218
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1
Zhang, Y., Griffith, E. C., Sage, J., Jacks, T., & Liu, J. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6427 · Cited by 175
Strategies for manipulating the p53 pathway in the treatment of human cancer
Hupp, T. R., Lane, D. P., & Ball, K. L. (2000) · Biochemical Journal · doi:10.1042/bj3520001 · Cited by 173
Isolation and Structure Elucidation of Chlorofusin, a Novel p53-MDM2 Antagonist from a Fusarium sp.
Duncan, S. J., Grüschow, S., Williams, D. H., McNicholas, C., Purewal, R., Hajek, M., Gerlitz, M., Martin, S., Wrigley, S. K., & Moore, M. (2001) · Journal of the American Chemical Society · doi:10.1021/ja002940p · Cited by 172
The loss of mdm2 induces p53 mediated apoptosis
de Rozìeres, S., Maya, R. B.-Y., Oren, M., & Lozano, G. (2000) · Oncogene · doi:10.1038/sj.onc.1203468 · Cited by 164
Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations
Nikolova, P. V., Wong, K., DeDecker, B., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 152
Self-citationBrachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 142
Kim, A. L., Raffo, A. J., Brandt‐Rauf, P. W., Pincus, M. R., Monaco, R. R., Abarzúa, P., & Fine, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34924 · Cited by 126
Anderson, M. E., Woelker, B., Reed, M. J., Wang, P., & Tegtmeyer, P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6255 · Cited by 120
Ghaneh, P., Greenhalf, W., Humphreys, M. J., Wilson, D., Zumstein, L. A., Lemoine, N. R., & Neoptolemos, J. P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301394 · Cited by 100
Hansen, S., Hupp, T. R., & Lane, D. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3917 · Cited by 96
Crystal Structure of the Mouse p53 Core DNA-binding Domain at 2.7 Å Resolution
Zhao, K., Chai, X., Johnston, K., Clements, A. M., & Marmorstein, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011644200 · Cited by 89
Flexibility: the key to p53 function?
Milner, J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)88954-9 · Cited by 88
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Specific DNA binding by different classes of human p53 mutants.
Rolley, N. J., Butcher, S., & Milner, J. (1995) · PubMed · Cited by 81
Mateu, M. G., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3595 · Cited by 74
Self-citationIn vitro analysis of the dominant negative effect of p53 mutants
Chêne, P. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1897 · Cited by 72
Regulation of p53 protein function through alterations in protein-folding pathways
Hupp, T. R. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050272 · Cited by 58
Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015
McCormick, F. P. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0336 · Cited by 57
Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo
Koga, H., & Deppert, W. (2000) · Oncogene · doi:10.1038/sj.onc.1203745 · Cited by 35
Stavridi, E. S., Caruso, L. C., Chehab, N. H., & Halazonetis, T. D. (1999) · Protein Science · doi:10.1110/ps.8.9.1773 · Cited by 15
Cohen, P. A., Hupp, T. R., Lane, D. P., & Daniels, D. A. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01603-8 · Cited by 13
Cited by
Protein folding and misfolding
Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Haupt, S., Berger, M., Goldberg, Z., & Haupt, Y. (2003) · Journal of Cell Science · doi:10.1242/jcs.00739 · Cited by 1,136
Metadata
- Authors
- Bullock, A. N., & Fersht, A. R.
- Venue
- Nature Reviews Cancer
- Published
- 2001-10
- Volume
- 1
- Issue
- 1
- Pages
- 68-76
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2047596219
- Cited by
- 568
- References
- 67
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.